🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We would like to welcome Devin Smith as SVP and General Counsel. Devin‘s experience providing legal guidance to biopharma companies will be invaluable as we continue to grow the clinical and financial facets of our company. Read more: bit.ly/3ghQN4t $YMTX

We are featured in a C&EN (Chemical & Engineering News) story about the role of lipids in #ParkinsonsDisease. EVP and Head of R&D, Ajay Verma, MD, PhD, shared his thoughts on the subject and how it relates to our lead candidate, YTX-7739. Read the article here: bit.ly/3ioxyWM Celia Arnaud

We are participating in a fireside chat at the #BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021, at 1 p.m. ET. Please contact your BTIG representative to listen to the live event. $YMTX

We have announced our second quarter 2021 financial results and an overview of recent corporate developments and upcoming milestones. Read more: bit.ly/3CJJ08L $YMTX #2Q2021

We're excited to welcome Michael D. Wyzga to the Yumanity team as our new SVP, CFO. Mike is an expert in healthcare finance and we look forward to his contributions in driving our financial strategy as we continue advancing our pipeline. Read more: bit.ly/3yQbV8T $YMTX

Members of our executive team are available for 1x1s during the Morgan Stanley 19th Annual Global Healthcare Conference, September 9-15. Please contact your Morgan Stanley representative to schedule a meeting. $YMTX

We congratulate our director, Jeffrey W. Kelly, PhD, on receiving the 2022 Breakthrough Prize in Life Sciences for his work in understanding protein clumping-associated CNS toxicity and inventing a treatment to slow disease progression. bit.ly/3BTtTs8 $YMTX

Our CEO, Richard Peters, MD, PhD, is presenting at the H.C. Wainwright 23rd Annual Global Investment Conference. The video presentation will be available starting Monday, September 13 at 7:00 AM EDT. View the webcast: bit.ly/3zY3OYA $YMTX

We look forward to presenting phase 0 results in collaboration with CHDR at the Movement Disorder Society Virtual Congress. The Ph0 study evaluated biomarkers for our SCD inhibitor, YTX-7739. Video will be available on demand starting Sept 17. $YMTX MDS

On Wednesday, November 3, Ajay Verma, MD, PhD, our EVP, Head of R&D, will discuss synuclein and lipid homeostasis at 12:15 – 12:25 PM EDT. $YMTX michaeljfox.org

Members of the Yumanity team are presenting at the Society for Neuroscience 50th Annual Meeting. Video presentations are available starting November 3 and round table discussions will take place November 9 and 11. Register here: bit.ly/3nQ88nA $YMTX Society for Neuroscience (SfN) #SfN21

Our EVP, Head of R&D, Ajay Verma, MD, PhD, is presenting at CNS Summit 2021 on Tuesday, November 9. Register here: bit.ly/31fsIpP $YMTX CNS Summit

Join our EVP, Head of R&D, Ajay Verma, at The Clinical Trials on Alzheimer's Disease conference Nov 9-12. He will present Phase 1 Single and Multiple Ascending Dose results of YTX-7739 in healthy subjects. Register here: bit.ly/3CGLc0j $YMTX CTAD #CTAD21

YTX-7739 achieved positive top-line results in our Phase 1b trial in #ParkinsonsDisease patients, demonstrating favorable PK/PD and engaging novel target SCD. Following this key milestone, we expect to start a Phase 2 trial in 2022. Read more: bit.ly/3CYVWHA $YMTX

We have announced our third quarter 2021 financial results and an overview of recent corporate developments and upcoming milestones. Read more: bit.ly/3Cj9JaE $YMTX #3Q2021

Our CEO, Richard Peters, MD, PhD, is presenting at the Stifel Healthcare Conference on Wed, Nov 17 at 9:20 – 9:50 AM EST. Dr. Peters will discuss our recent Phase 1b study of YTX-7739 in #ParkinsonsDisease patients. Please contact your Stifel representative to register. $YMTX

Our webcast at the Jefferies London Healthcare Conference will be available on demand November 18-19. Join our CEO, Richard Peters, MD, PhD, as he discusses our recent Phase 1b YTX-7739 study. Please contact your Jefferies representative to register. $YMTX

We are proud to be awarded a grant from michaeljfox.org to further investigate efficacy and biomarker development of our clinical-stage stearoyl-CoA desaturase inhibitor, YTX-7739 in development as a treatment for #Parkinsonsdisease. Read more: bit.ly/3tgovy5 $YMTX

Our collaboration with Merck on our #ALS and #FTLD program has achieved its first research milestone and we have received a $5M milestone payment. Our work together has been very productive, and we look forward to future progress. Read more: bit.ly/3tgovy5 $YMTX

Now in Molecular Neurobiology: Preclinical pharmacology of our lead #ParkinsonsDisease candidate, YTX-7739, shows dose-dependent decreases in brain FADI ~to plasma; supports plasma FADI as surrogate clinical development biomarker. Read more: bit.ly/3IhRYfo $YMTX